TAP2 and non-small cell lung carcinoma: The fraction of cases displaying TAP1 and TAP2 alterations in our study is higher than previous studies in NSCLC ranging from 2.1–7.9% and 18.7–28.78%, respectively using genomic/transcriptomics and chromogenic immunohistochemistry.